[
  {
    "title": "港股异动 | 诺诚健华-B涨5% 治疗复发/难治性弥漫性大B细胞淋巴瘤Tafasitamab联合来那度胺在中国香港获批",
    "href": "http://stock.jrj.com.cn/2022/12/29094637245311.shtml",
    "datetime": "2022-12-29 09:46:35",
    "code": "688428"
  },
  {
    "title": "诺诚健华(9969.HK/688428.SH)：下一个“隐形成长冠军”",
    "href": "http://stock.jrj.com.cn/2022/12/28122537242625.shtml",
    "datetime": "2022-12-28 12:25:33",
    "code": "688428"
  },
  {
    "title": "诺诚健华：Tafasitamab联合来那度胺在香港获批用于治疗复发/难治性弥漫性大B细胞淋巴瘤",
    "href": "http://stock.jrj.com.cn/2022/12/28081437242043.shtml",
    "datetime": "2022-12-28 08:14:07",
    "code": "688428"
  },
  {
    "title": "港股异动 | 诺诚健华AH股齐升 BTK抑制剂联合疗法在中国获批2期临床试验",
    "href": "http://stock.jrj.com.cn/2022/12/23104937233509.shtml",
    "datetime": "2022-12-23 10:49:56",
    "code": "688428"
  },
  {
    "title": "诺诚健华AH股均涨超10% H股股价创约5个月新高",
    "href": "http://stock.jrj.com.cn/2022/12/09124837201010.shtml",
    "datetime": "2022-12-09 12:48:38",
    "code": "688428"
  },
  {
    "title": "诺诚健华宣布宜诺凯(奥布替尼)在新加坡获批用于治疗套细胞淋巴瘤",
    "href": "http://stock.jrj.com.cn/2022/11/22124337156938.shtml",
    "datetime": "2022-11-22 12:43:49",
    "code": "688428"
  },
  {
    "title": "诺诚健华（9969.HK/688428.SH）：收益领跑科创Biotech，Q3产品放量加速",
    "href": "http://stock.jrj.com.cn/2022/11/15082837139017.shtml",
    "datetime": "2022-11-15 08:28:54",
    "code": "688428"
  },
  {
    "title": "诺诚健华三季报：科创板上市注入新动能 奥布替尼收入持续提升",
    "href": "http://stock.jrj.com.cn/2022/11/14083337135519.shtml",
    "datetime": "2022-11-14 08:33:18",
    "code": "688428"
  },
  {
    "title": "诺诚健华：三季度亏损3.93亿元",
    "href": "http://stock.jrj.com.cn/2022/11/13193837134658.shtml",
    "datetime": "2022-11-13 19:38:46",
    "code": "688428"
  },
  {
    "title": "诺诚健华：10项奥布替尼研究入选第64届美国血液学协会（ASH）年会",
    "href": "http://stock.jrj.com.cn/2022/11/08090137119379.shtml",
    "datetime": "2022-11-08 09:01:20",
    "code": "688428"
  },
  {
    "title": "诺诚健华AH股齐拉升 研究结果表明奥布替尼单药治疗复发/难治性华氏巨球蛋白血症具有良好的安全性",
    "href": "http://stock.jrj.com.cn/2022/10/18142537063660.shtml",
    "datetime": "2022-10-18 14:25:33",
    "code": "688428"
  },
  {
    "title": "两地上市也无利好？科创板股价不佳，仍未盈利的诺诚健华怎么办？",
    "href": "http://stock.jrj.com.cn/ipo/2022/10/10161937043935.shtml",
    "datetime": "2022-10-10 16:19:55",
    "code": "688428"
  },
  {
    "title": "资金使用效率王者诺诚健华（9969.HK/688428.SH）登陆科创板",
    "href": "http://stock.jrj.com.cn/2022/09/23100037016260.shtml",
    "datetime": "2022-09-23 10:00:21",
    "code": "688428"
  },
  {
    "title": "诺诚健华(688428)：将于2022年9月21日在上海证券交易所科创板上市",
    "href": "http://stock.jrj.com.cn/2022/09/20090637006934.shtml",
    "datetime": "2022-09-20 09:06:36",
    "code": "688428"
  },
  {
    "title": "诺诚健华(688428.SH)披露中签结果：中签号码共有14.37万个",
    "href": "http://stock.jrj.com.cn/2022/09/13191336992127.shtml",
    "datetime": "2022-09-13 19:13:05",
    "code": "688428"
  },
  {
    "title": "诺诚健华(688428.SH)：网上发行最终中签率约为0.06010960%",
    "href": "http://stock.jrj.com.cn/2022/09/12160336989317.shtml",
    "datetime": "2022-09-12 16:03:29",
    "code": "688428"
  },
  {
    "title": "盘前有料丨诺诚健华今日申购；富安娜澄清固收理财产品逾期兑付相关传闻…重要消息还有这些",
    "href": "http://stock.jrj.com.cn/2022/09/09033636984796.shtml",
    "datetime": "2022-09-09 03:36:26",
    "code": "688428"
  },
  {
    "title": "IPO打新观察：诺诚健华发行价11.03元，大成国际网下打新报出79.35元天价",
    "href": "http://stock.jrj.com.cn/ipo/2022/09/08151336983149.shtml",
    "datetime": "2022-09-08 15:13:20",
    "code": "688428"
  },
  {
    "title": "诺诚健华(688428)：发行价格确定11.03元/股，发行日期2022年9月9日（T日）",
    "href": "http://stock.jrj.com.cn/2022/09/08085936982116.shtml",
    "datetime": "2022-09-08 08:59:50",
    "code": "688428"
  },
  {
    "title": "诺诚健华(688428.SH)IPO定价为11.03元/股 9月9日开启申购",
    "href": "http://stock.jrj.com.cn/2022/09/07190536981099.shtml",
    "datetime": "2022-09-07 19:05:33",
    "code": "688428"
  },
  {
    "title": "从“专精特新”看诺诚健华（9969.HK/688428.SH）投资逻辑",
    "href": "http://stock.jrj.com.cn/2022/09/05090936972518.shtml",
    "datetime": "2022-09-05 09:09:53",
    "code": "688428"
  },
  {
    "title": "诺诚健华(688428)：首发264648217股，询价日期为2022年9月6日周二",
    "href": "http://stock.jrj.com.cn/2022/09/01090636961424.shtml",
    "datetime": "2022-09-01 09:06:42",
    "code": "688428"
  },
  {
    "title": "诺诚健华-B：2022年上半年归母亏损同比扩大110.75%至4.41亿元",
    "href": "http://stock.jrj.com.cn/2022/08/22105336920595.shtml",
    "datetime": "2022-08-22 10:53:55",
    "code": "688428"
  },
  {
    "title": "诺诚健华-B预计2022年中期综合收入增长不少于132.2%",
    "href": "http://stock.jrj.com.cn/2022/08/05135836873402.shtml",
    "datetime": "2022-08-05 13:58:33",
    "code": "688428"
  },
  {
    "title": "银行存款59亿还频繁募资 诺诚健华IPO动机遭疑且研发滞后",
    "href": "http://stock.jrj.com.cn/2022/07/25095236839472.shtml",
    "datetime": "2022-07-25 09:52:00",
    "code": "688428"
  },
  {
    "title": "睿昂基因携手诺诚健华 构建更完善的淋巴瘤基因检测体系",
    "href": "http://stock.jrj.com.cn/2022/07/04173536780513.shtml",
    "datetime": "2022-07-04 17:35:20",
    "code": "688428"
  },
  {
    "title": "施一公创立、高瓴资本加持，这家银行存款59.2亿的医药公司，准备在科创板募资40亿！",
    "href": "http://stock.jrj.com.cn/ipo/2022/04/20084836406392.shtml",
    "datetime": "2022-04-20 08:48:20",
    "code": "688428"
  },
  {
    "title": "施一公主导，高瓴资本加持，这家创新医药公司冲刺A+H股上市",
    "href": "http://stock.jrj.com.cn/2022/04/14202736337529.shtml",
    "datetime": "2022-04-14 20:27:45",
    "code": "688428"
  },
  {
    "title": "科创板上市委：诺诚健华首发获通过",
    "href": "http://stock.jrj.com.cn/2022/04/12203536317191.shtml",
    "datetime": "2022-04-12 20:35:32",
    "code": "688428"
  },
  {
    "title": "“施一公概念股”诺诚健华回归A股冲关：神秘关联公司真实身份待考！累积亏损35亿，募投12亿补流引争议",
    "href": "http://stock.jrj.com.cn/ipo/2022/04/12081936312175.shtml",
    "datetime": "2022-04-12 08:19:46",
    "code": "688428"
  },
  {
    "title": "诺诚健华无控股股东和实际控制人，多个股东无法穿透至最终持有人，科创板上市圈钱动机明显",
    "href": "http://stock.jrj.com.cn/ipo/2022/04/08083636270813.shtml",
    "datetime": "2022-04-08 08:36:40",
    "code": "688428"
  },
  {
    "title": "诺诚健华两轮问询回复迎上会，4月12日接受IPO审核",
    "href": "http://stock.jrj.com.cn/2022/04/06112336261609.shtml",
    "datetime": "2022-04-06 11:23:50",
    "code": "688428"
  },
  {
    "title": "科创属性几何？诺诚健华答复科创板IPO二轮问询",
    "href": "http://stock.jrj.com.cn/2022/03/28111135821610.shtml",
    "datetime": "2022-03-28 11:11:44",
    "code": "688428"
  },
  {
    "title": "诺诚健华首答科创板问询，多地上市、司法管辖等被注意",
    "href": "http://stock.jrj.com.cn/2021/11/19112933878522.shtml",
    "datetime": "2021-11-19 11:29:37",
    "code": "688428"
  },
  {
    "title": "“A+H”再进一步！诺诚健华科创板IPO获上交所问询",
    "href": "http://stock.jrj.com.cn/2021/10/18092833709064.shtml",
    "datetime": "2021-10-18 09:28:31",
    "code": "688428"
  },
  {
    "title": "诺诚健华尚未盈利融资或超百亿 2020年研发费4.23亿四成为股权激励",
    "href": "http://stock.jrj.com.cn/ipo/2021/09/27070533696491.shtml",
    "datetime": "2021-09-27 07:05:05",
    "code": "688428"
  },
  {
    "title": "诺诚健华谋求科创板二次上市 手握超60亿元仍大额募资",
    "href": "http://stock.jrj.com.cn/ipo/2021/09/24081833508307.shtml",
    "datetime": "2021-09-24 08:18:55",
    "code": "688428"
  },
  {
    "title": "港股上市公司诺诚健华冲刺科创板IPO，亏损超30亿在研产品商业化未明",
    "href": "http://stock.jrj.com.cn/2021/09/14091233432259.shtml",
    "datetime": "2021-09-14 09:12:29",
    "code": "688428"
  },
  {
    "title": "谋求A+H？港股上市公司诺诚健华科创板上市辅导已完成",
    "href": "http://stock.jrj.com.cn/2021/09/07171933399008.shtml",
    "datetime": "2021-09-07 17:19:01",
    "code": "688428"
  },
  {
    "title": "抗癌创新药研发商诺诚健华拟科创板二次上市，2月刚引入高瓴战投",
    "href": "http://stock.jrj.com.cn/ipo/2021/04/22084032420908.shtml",
    "datetime": "2021-04-22 08:40:10",
    "code": "688428"
  },
  {
    "title": "诺诚健华拟引入高瓴资本作为战略投资者 今日收涨逾17%",
    "href": "http://stock.jrj.com.cn/2021/02/03182931844332.shtml",
    "datetime": "2021-02-03 18:29:54",
    "code": "688428"
  },
  {
    "title": "两大竞争对手均入医保，诺诚健华首个落地抗癌靶向药如何破局？",
    "href": "http://stock.jrj.com.cn/2021/01/06161931641824.shtml",
    "datetime": "2021-01-06 16:19:09",
    "code": "688428"
  },
  {
    "title": "诺诚健华-B肿瘤创新药奥布替尼获国家药监局批准上市",
    "href": "http://stock.jrj.com.cn/2020/12/26113031574733.shtml",
    "datetime": "2020-12-26 11:30:31",
    "code": "688428"
  },
  {
    "title": "诺诚健华BTK抑制剂奥布替尼片即将获批上市",
    "href": "http://stock.jrj.com.cn/2020/12/18205731520860.shtml",
    "datetime": "2020-12-18 20:57:26",
    "code": "688428"
  },
  {
    "title": "每经数说丨3月下半月新药研发：豪森药业1类新药阿美乐获批， 默沙东、恒瑞医药、诺诚健华研发有突破",
    "href": "http://stock.jrj.com.cn/2020/04/07121329224426.shtml",
    "datetime": "2020-04-07 12:13:28",
    "code": "688428"
  },
  {
    "title": "港交所上市仪式明起“云敲锣” 施一公领衔诺诚健华尝鲜",
    "href": "http://stock.jrj.com.cn/2020/03/22200329076267.shtml",
    "datetime": "2020-03-22 20:03:00",
    "code": "688428"
  },
  {
    "title": "诺诚健华启动港股招股 预计3月23日上市",
    "href": "http://stock.jrj.com.cn/2020/03/11164629001786.shtml",
    "datetime": "2020-03-11 16:46:47",
    "code": "688428"
  },
  {
    "title": "[利德曼]喜讯:利德曼喜迎高新科控和诺诚健华来访 开展产业互动交流",
    "href": "http://stock.jrj.com.cn/2019/04/19000027432311.shtml",
    "datetime": "2019-04-19 00:00:00",
    "code": "688428"
  }
]